“Giving your best systemic therapy first could act on occult metastatic disease and possibly improve systemic disease control,” he said. The risks include progression that precludes definitive therapy and possibly more pneumonitis.
No trial has reported induction plus a PACIFIC-like approach vs a PACIFIC-like approach alone. The phase 3 GASTO-10124 trial (NCT06734702) is randomly assigning a planned 497 patients to induction tislelizumab-jsgr (Tevimbra) plus chemotherapy followed by hypofractionated or conventional chemoradiotherapy, or to chemoradiotherapy alone, with tislelizumab consolidation in all arms and 18-month PFS as the primary end point.5
Early lessons were derived from the nonrandomized phase 2 MDT-BRIDGE trial (NCT05925530), in which patients (n = 142) with resectable (65%) or borderline resectable (35%) disease received 2 cycles of induction durvalumab plus chemotherapy before multidisciplinary reassessment. The resection rate, the primary end point, was 75%.6
Overall, 92% of patients received definitive therapy: 106 underwent resection and 25 received chemoradiotherapy. Shaverdian called that the greater takeaway, “suggesting that with this approach, we’re likely not causing harm, as most patients receive definitive therapy.” Only 3 patients had disease progression during induction.1,6
Among the 25 patients treated with chemoradiotherapy, the 12-month PFS rate was 85% (95% CI, 60%-95%); the 12-month event-free survival (EFS) rate was 93% (95% CI, 86%-97%) among the 106 patients who underwent resection.6
“There appears to be some added toxicity during chemoradiation,” Shaverdian said. “Specifically, 8% of patients developed pneumonitis during chemoradiation, and that’s generally not something we expect in the absence of induction.”
The events were mainly low grade, and no grade 3/4 pneumonitis or immune-mediated adverse effects (AEs) occurred during chemoradiotherapy or consolidation.6
Could response to induction personalize radiotherapy?
Induction also raises new questions for radiation planning. Under the current standard, the primary tumor is treated to its post-induction extent, whereas nodal regions cover pretreatment involvement, with standard expansions and uniform dosing.1 Shaverdian presented a patient whose nodal disease had a complete metabolic and radiographic response to induction.
“[However], with our current standard of care, we would treat this as if there was bulky residual disease, and this raises some key questions,” he said, highlighting whether elective expansions can be reduced, whether dose can be adapted to response, and whether ctDNA could inform those choices.
MDT-BRIDGE offered early signals, with most evaluable patients (99%) being ctDNA positive at baseline, and 37% cleared ctDNA after induction.7 With clearance, the 12-month EFS rate was 100% after surgery (n = 28) vs 88.9% with detectable ctDNA (n = 40), and the 12-month PFS rate was 100% after chemoradiotherapy (n = 4) vs 77.5% with detectable ctDNA (n = 16).
Shaverdian cautioned that the numbers were “very small,” especially with the chemoradiotherapy approach.
“However, [these data] suggest that, potentially, we could use molecular data in addition to imaging data to guide some of our local therapy decision-making,” he explained.
What comes next for induction-based strategies?
Shaverdian closed with the recently IRB-approved phase 2 INSPIRE trial at Memorial Sloan Kettering, which he leads with Jamie Chaft, MD.1 The study enrolls patients with stage IIB (N2) to III NSCLC and a PD-L1 tumor proportion score below 50%, a group with a greater than 50% chance of distant relapse. Patients will receive 2 cycles of the PD-1/VEGF bispecific ivonescimab plus chemotherapy, then chemoradiotherapy to 60 Gy adapted to the post-induction disease volume without elective expansions, then ivonescimab consolidation. Nodal areas with a complete response receive 44 Gy, which Shaverdian said is more in line with postoperative dosing for microscopic disease. The primary end point is 12-month PFS.
“The goal is that this combined approach maintains safety and improves outcomes in these higher-risk patients,” he concluded.
References
- Shaverdian N. Looking beyond PACIFIC: emerging strategies in locally advanced NSCLC. Presented at: 21st Annual New York Lung Cancers Symposium; November 14, 2026; New York, NY.
- Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. N Engl J Med. 2017;377(20):1919-1929. doi:10.1056/NEJMoa1709937
- Adaptive ctDNA-based personalization of treatment during consolidation therapy in NSCLC. Accessed November 17, 2026. https://clinicaltrials.gov/study/NCT04585490
- ctDNA-guided consolidation immunotherapy after chemoradiotherapy in patients with stage III non-small cell lung cancer (IDEATION). Updated August 12, 2026. Accessed November 17, 2026. https://clinicaltrials.gov/study/NCT07759492
- Neoadjuvant immunotherapy plus chemotherapy followed by concurrent chemoradiotherapy and consolidative immunotherapy for locally advanced non-small cell lung cancer (GASTO-10124). ClinicalTrials.gov. Updated July 24, 2025. Accessed November 17, 2026. https://clinicaltrials.gov/study/NCT06734702
- Reck M, Nadal E, Gay CM, et al. Neoadjuvant durvalumab + chemotherapy for resectable/borderline resectable stage IIB-IIIB NSCLC: MDT-BRIDGE primary analysis. Presented at: IASLC 2026 World Conference on Lung Cancer; September 12-15, 2026; Seoul, South Korea. Abstract OA04.02.
- Spicer J, Gale D, Reck M, et al. ctDNA clearance during neoadjuvant treatment and its association with outcomes in patients with resectable/borderline resectable stage IIB–IIIB NSCLC from MDT-BRIDGE. Presented at: 2026 ESMO Congress; October 23-27, 2026; Madrid, Spain. Abstract LBA62.